There is an increasing trend towards switching patients to FF/Vi therapy in uncontrolled, exacerbating, and symptomatic OAD patients with various comorbidities, which might be attributable to its previously reported evidence in reducing exacerbations, symptom control, and cardiovascular safety.
← all excerpts
Fluticasone Furoate/Vilanterol Use Trends and Characteristics in Patients With Obstructive Airway Disease: A Real-World Study of 10,374 Patients From India.
1
—
—